ArriVent BioPharma, Inc. (AVBP) stock
AVBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.69−0.87 (-7.53%)
Close on Nov 17, 2026Market cap $527.10MP/E –Yield –
ArriVent BioPharma r&d expenses
Research and development expenses are spending on new products and technology.
ArriVent BioPharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $144.30M, up 11.6% year over year. For fiscal 2025 it was $153.35M, up 94.1% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $153.35M | +94.1% |
| FY2024 | Dec 31, 2024 | $79.00M | +21.8% |
| FY2023 | Dec 31, 2023 | $64.88M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $42.34M | +52.7% |
| Q1 FY2026 | Mar 31, 2026 | $37.62M | -38.6% |
| Q4 FY2025 | Dec 31, 2025 | $32.18M | +59.6% |
| Q3 FY2025 | Sep 30, 2025 | $32.17M | +60.1% |
| Q2 FY2025 | Jun 30, 2025 | $27.72M | +27.3% |
| Q1 FY2025 | Mar 31, 2025 | $61.29M | +261.1% |
| Q4 FY2024 | Dec 31, 2024 | $20.16M | +0.8% |
| Q3 FY2024 | Sep 30, 2024 | $20.09M | +40.7% |
| Q2 FY2024 | Jun 30, 2024 | $21.78M | +7.0% |
| Q1 FY2024 | Mar 31, 2024 | $16.98M | +65.8% |
| Q4 FY2023 | Dec 31, 2023 | $20.01M | – |
| Q3 FY2023 | Sep 30, 2023 | $14.28M | – |
| Q2 FY2023 | Jun 30, 2023 | $20.36M | – |
| Q1 FY2023 | Mar 31, 2023 | $10.24M | – |
See a number that looks wrong?